<a href="http://tamoxifenolvadex.com/" / rel="nofollow ugc">chance of breast cancer recurrence without tamoxifen</a> In the context of NSABP B-30 trial, 5351 patients were randomly assigned to four cycles of doxorubicin and cyclophosphamide followed by four cycles of docetaxel AC T vs four cycles of doxorubicin and docetaxel and vs four cycles of doxorubicin, cyclophosphamide, and docetaxel Swain et al, 2010.